Fuller & Thaler Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Fuller & Thaler Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-500	Closed	-$81K	–	780
2018 Q1	$81K	Sell	500 -800	-62%	-$131K	﹤0.01%	603
2017 Q4	$195K	Hold	1,300	–	–	﹤0.01%	432
2017 Q3	$198K	Buy	+1,300	New	+$196K	﹤0.01%	404
2013 Q4	–	Sell	-1,700	Closed	-$129K	–	634
2013 Q3	$129K	Sell	1,700 -3,500	-67%	-$279K	0.01%	458
2013 Q2	$416K	Buy	+5,200	New	+$383K	0.03%	296

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Fuller & Thaler Asset Management's VRTX Position: Q2 2018 in Review

Fuller & Thaler Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2018, closing a stake of 500 shares — an estimated $81K sold.

Fuller & Thaler Asset Management first reported a position in VRTX in Q2 2013 and held it in 5 quarters. The position peaked at $416K in Q2 2013. 690 funds tracked by Wall St. Rank hold VRTX as of Q2 2018.

Fuller & Thaler Asset Management reported no remaining Vertex Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Fuller & Thaler Asset Management sold 500 Vertex Pharmaceuticals shares in Q2 2018, an estimated $81K.
Fuller & Thaler Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 5 quarters.
Fuller & Thaler Asset Management's Vertex Pharmaceuticals position peaked at $416K in Q2 2013.
690 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2018.

Based on Fuller & Thaler Asset Management's 13F filing for Q2 2018, filed 7 Aug 2018.